Topic resource collection
Approved comparison material connected to this topic.
479 resourcesRead both sides
NSAIDs: Fast pain relief (hours) Don't heal tissue GI side effects Cardiovascular risks long-term Can impair healing Peptides: Gradual improvement (weeks) Actually heal tissue Minimal side effects Safe long-term Promote healing V…
PRP (Platelet-Rich Plasma): Medical procedure ($500-2,000 per injection) Good clinical evidence 1-3 injections needed Professional administration Daily administration Much more affordable Verdict: PRP has more clinical backing. P…
Thymalin Thymic epithelial stimulation, increases CD4+/CD8+ differentiation 5–10mg SC twice weekly for 10–20 days CD4+ count increase 12–28%, thymulin levels normalize within 4 weeks Gold standard for T-cell restoration in viral …
Thymalin T-regulatory cell differentiation, IL-10/TGF-beta upregulation Immune dysregulation, chronic inflammation, Th17 dominance 5–10mg SC 2–3×/week, 8–12 weeks Human RCTs in autoimmune conditions; reduced IL-17 40–55% Stronges…
| Compound | Primary Mechanism | HPG Axis Impact | Typical Research Dose | Time to Measurable Effect | Recovery After Cessation | Professional Assessment ||—|—|—|—|—|—|| Gonadorelin | GnRH receptor agonist. Stimulates LH/FSH rele…
CJC-1295 + Ipamorelin Dual-pathway GH secretagogue. Pulsatile release preserves physiological rhythm Small Phase 2 trials show improved oocyte yield in poor responders; no large RCTs 200–250 mcg each peptide subcutaneously before…
Thymalin Restores thymic epithelial function and T-cell differentiation Thymus, immune system 10mg SC daily × 10 days 4–6 weeks for normalised CD4/CD8 First-line for immune dysregulation. Addresses root cause of autoimmune-like s…
Thymalin Thymic peptide signalling, T-cell regulation Immune-dominant (elevated cytokines, NK cell dysfunction) 2–3x weekly subcutaneous Moderate (published cytokine normalisation data in post-viral fatigue) Best first-line choic…
Thymalin Thymic epithelial cell activation → T-cell maturation and thymulin secretion Immunosenescence and declining adaptive immunity 5–10mg subcutaneous, 10-day cycles Subcutaneous injection after reconstitution in bacteriostat…
Understanding which peptide fits which aging mechanism requires side-by-side comparison of targets, bioavailability, and evidence quality. P21 CREB pathway activation → synaptic protein synthesis without BDNF dependence Subcutane…
BPC-157 NF-kB inhibition, VEGF upregulation, nitric oxide stabilisation Chronic widespread pain, inflammation, tissue hypoxia 200–500 mcg/day subcutaneous Preclinical models + case series Strongest anti-inflammatory profile. Addr…
The table below compares the primary peptide classes used in anti-aging protocols for men over 40, detailing mechanism, dosing, and professional assessment. Growth Hormone Secretagogues (CJC-1295 + Ipamorelin) GHRH and ghrelin re…
Thymalin T-cell modulation; Treg upregulation Moderate (Eastern European clinical trials) 5–10mg subcutaneous, 2–3 times weekly 22–34% reduction in anti-TPO titres over 12 weeks in 2018 study Strongest evidence for immune recalib…
This table compares the mechanisms, clinical evidence, and practical considerations for peptides with documented or theoretical stroke-prevention effects. Cerebrolysin Neurotrophic factor mimetic (BDNF, NGF pathways) 6 RCTs in ac…
LL-37 (Cathelicidin) Direct antimicrobial activity via bacterial membrane disruption MIC against E. coli and Enterococcus at 2–8 μg/mL; SIBO patients show 58% reduced LL-37 expression Not available as exogenous peptide; upregulat…
Dihexa HGF receptor agonist; stimulates synaptogenesis in prefrontal cortex 40–60% oral; crosses BBB efficiently 0.25–2mg daily, oral or subcutaneous Increased synaptic density 300% in rodent PFC; sustained cognitive benefit 4 we…
| Peptide | Primary Mechanism | Lupus-Relevant Pathway | Studied Dosage Range | Half-Life | Bottom Line ||—|—|—|—|—|| Thymalin | Thymic T-cell regulation | Restores central tolerance; reduces autoreactive T-cell activation | 5–20…
Thymalin T-regulatory cell differentiation via thymulin receptor activation CD4+ T-cells in thymic tissue and peripheral circulation Minimal. Acts systemically on immune organs, not CNS-direct 10–30mg SC daily, 10-day cycles Shor…
This table compares the primary peptides studied in rosacea and inflammatory dermatoses based on mechanism, clinical evidence quality, typical concentration ranges, and practical considerations for formulation stability. KPV (Lys…
BPC-157 VEGF modulation, NF- B inhibition, stellate cell suppression 200–500 mcg SQ daily (human equivalent from animal models) Preclinical only. No Phase III human trials Strongest evidence for fibrosis reduction in CCl4 and alc…